BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• 

  Drug Development

  Gene Editing, Next-Gen Antibodies Key to Unlocking Animal-to-Human Transplants

  It’s early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions to make this approach a viable option and help ease the organ shortage crisis.

  March 24, 2025

   · 

  8 min read

   · 

  Kate Goodwin
• 

  IN PARTNERSHIP WITH SMARTLABS

  How Modern Vivarium Services Are Revolutionizing Drug Development

  In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.

  March 24, 2025

   · 

  7 min read

   · 

  BioSpace Insights
• 

  Spinal muscular atrophy

  6 Therapies on the Horizon for Spinal Muscular Atrophy

  Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several companies—including Novartis, Scholar Rock and Biogen—progressing novel candidates through clinical trials.

  March 24, 2025

   · 

  5 min read

   · 

  Natalia Mesa
• 

  Legal

  AbbVie Lawsuit Alleges That Partner Genmab “Misappropriated” Trade Secrets

  AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s investigational antibody-drug conjugates. Genmab acquired ProfoundBio in May 2024.

  March 24, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Weight loss

  Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech

  Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a mid-stage study.

  March 24, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  China

  AstraZeneca Makes Potential $10B+ China Commitment Despite Political Pressure

  The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite mounting pressure from President Trump for pharma companies to re-shore their manufacturing operations.

  March 24, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Venture capitalists

  Tempero Raises $70M to Fight Substance Use Disorders

  The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat alcohol- and cocaine-use disorders, among other indications.

  March 24, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Opinion

  Biosimilars Shouldn’t Be This Hard To Bring to Market

  Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of branded biologics looking to maintain blockbuster revenue.

  March 24, 2025

   · 

  7 min read

   · 

  Sarfaraz K. Niazi
• Press Releases

  Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

  March 24, 2025

   · 

  6 min read
• Press Releases

  CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

  March 24, 2025

   · 

  7 min read